Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Company Overview - Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics for patients in need [5] - The company's lead molecule, azetukalner, is a novel KV7 potassium channel opener currently in Phase 3 clinical trials for treating epilepsy, major depressive disorder (MDD), and bipolar depression (BPD) [5] - Xenon is also advancing an early-stage portfolio of potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for potential pain treatment [5] Recent Financial Activity - Xenon Pharmaceuticals announced the closing of an underwritten public offering of 12,236,843 common shares, which includes 1,710,526 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase up to 877,194 common shares [1] - The common shares were offered at a public offering price of $57.00 per share, while the pre-funded warrants were offered at a price of $56.9999, with an exercise price of $0.0001 [1] - The aggregate gross proceeds from the offering were approximately $747.5 million before deducting underwriting discounts and commissions and other offering expenses [1] Underwriting and Regulatory Information - J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair acted as joint book-running managers for the offering, with Baird serving as the lead manager [2] - An automatically effective shelf registration statement relating to the securities offered was filed with the SEC on August 9, 2024, and the final prospectus supplement was filed on March 11, 2025 [3]